Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2015

01-04-2015 | Editorial

Note of clarification of data in the paper titled X-ray repair cross-complementing group 1 Arg194Trp polymorphism is associated with increased risk of lung cancer in Chinese Han population

Authors: Haiyan Yang, Ruo Feng, Haiyu Wang, Yadong Wang

Published in: Tumor Biology | Issue 4/2015

Login to get access

Excerpt

We read with great interest the paper titled “X-ray repair cross-complementing group 1 Arg194Trp polymorphism is associated with increased risk of lung cancer in Chinese Han population” published in Tumor Biol. 2013, 34: 2611–2615 [1]. Wu et al. performed a meta-analysis to investigate the association between X-ray repair cross-complementing group 1 (XRCC1) Arg194Trp polymorphism and lung cancer risk in Chinese Han population on the basis of 12 case-control studies with 4385 cases and 4545 controls. The authors found that XRCC1 Arg194Trp polymorphism was associated with increased risk of lung cancer in Chinese Han population under three main models (allele contrast model, odds ratio (OR) = 1.12, 95 % confidence interval (CI) 1.00–1.26, P = 0.049; homozygote model, OR = 1.27, 95 % CI 1.09–1.48, P = 0.003; recessive model, OR = 1.26, 95 % CI 1.09–1.46, P = 0.003) when all eligible studies were pooled into meta-analysis. It is an interesting study. …
Literature
1.
Wu T, Xu YH, Ye XL. X-ray repair cross-complementing group 1 Arg194Trp polymorphism is associated with increased risk of lung cancer in Chinese Han population. Tumour Biol. 2013;34:2611–5.CrossRefPubMed
2.
Yin J, Vogel U, Ma Y, Qi R, Wang H. Association of DNA repair gene XRCC1 and lung cancer susceptibility among nonsmoking Chinese women. Cancer Genet Cytogenet. 2009;188:26–31.CrossRefPubMed
3.
Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, Andersen MR, Barrett MJ, et al. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10:119–23.PubMed
4.
Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet. 2005;162:10–20.CrossRefPubMed
5.
Song Y, Yin L, Pu Y, Liang G, Cui H. Relationship between polymorphisms of DNA repair gene XRCC1 and susceptibility to lung cancer in Nanjing population. J Labour Med. 2004;21:18–21.
6.
Yu H, Zeng X, Chou X, Xu S, Shi L, Zhang X, et al. Polymorphism in the DNA repair gene XRCC1 and susceptibility to human lung cancer. J Guangxi Med Univ. 2006;23:355–8.
7.
Chen S, Tang D, Xue K, Xu L, Ma G, Hsu Y, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis. 2002;23:1321–5.CrossRefPubMed
8.
Du Y, Chu DJ, Shi JM, Fan W. The relationship between lung cancer and genetic polymorphism of XRCC1. J Clin Intern Med. 2012;29:346–8.
9.
Du Y, He Y, Mei Z, Qian L, Shi J, Jie Z. Association between genetic polymorphisms in XPD and XRCC1 genes and risks of non-small cell lung cancer in East Chinese Han population. Clin Respir J. 2014. doi:10.​1111/​crj.​12218.PubMed
10.
Guo S, Li X, Gao M, Li Y, Song B, Niu W. The relationship between XRCC1 and XRCC3 gene polymorphisms and lung cancer risk in northeastern Chinese. PLoS One. 2013;8:e56213.CrossRefPubMedPubMedCentral
11.
Hao B, Miao X, Li Y, Zhang X, Sun T, Liang G, et al. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene. 2006;25:3613–20.CrossRefPubMed
12.
Hu Z, Ma H, Lu D, Zhou J, Chen Y, Xu L, et al. A promoter polymorphism (−77T>C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet Genomics. 2005;15:457–63.CrossRefPubMed
13.
Li M, Yin Z, Guan P, Li X, Cui Z, Zhang J, et al. XRCC1 polymorphisms, cooking oil fume and lung cancer in Chinese women nonsmokers. Lung Cancer. 2008;62:145–51.CrossRefPubMed
14.
Shen M, Berndt SI, Rothman N, Mumford JL, He X, Yeager M, et al. Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei. China Anticancer Res. 2005;25:537–42.PubMed
15.
Su J, Niu RG, Han XY, Shi JP, Liu L, Li JW, et al. Polymorphisms of DNA repair gene XRCC1 codon194 and its susceptibility to lung cancer. Fudan Univ J Med Sci. 2008;35:348–52.
16.
Wang N, Wu Y, Zhou X. Association between genetic polymorphism of metabolizing enzymes and DNA repairing enzymes and the susceptibility of lung cancer in Henan population. Wei Sheng Yan Jiu. 2012;41:251–6.PubMed
17.
Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer. 2007;56:153–60.CrossRefPubMed
18.
Zhang W, Wu Y, Wu Y. Study on polymorphism of XRCC1 and susceptibility to lung cancer. China Public Health. 2005;5:561–3.
Metadata
Title
Note of clarification of data in the paper titled X-ray repair cross-complementing group 1 Arg194Trp polymorphism is associated with increased risk of lung cancer in Chinese Han population
Authors
Haiyan Yang
Ruo Feng
Haiyu Wang
Yadong Wang
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3201-0

Other articles of this Issue 4/2015

Tumor Biology 4/2015 Go to the issue

Research Article

Distinct prognostic values of ALDH1 isoenzymes in breast cancer

Research Article

Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening

Research Article

EMSY promoted the growth and migration of ovarian cancer cells

Research Article

Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes

Research Article

miR-194 targets RBX1 gene to modulate proliferation and migration of gastric cancer cells

Review

COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits